Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

BACKGROUND: The combination of lenvatinib plus pembrolizumab has shown efficacy in treatment of advanced endometrial carcinoma (that is not microsatellite instability–high or mismatch repair deficient) following prior systemic therapy in any setting in the open‐label, single‐arm, phase Ib/II Study 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Makker, Vicky, Taylor, Matthew H., Oaknin, Ana, Casado Herraez, Antonio, Orlowski, Robert, Dutta, Lea, Ren, Min, Zale, Melissa, O'Malley, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Gynecologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417842/
https://www.ncbi.nlm.nih.gov/pubmed/34190370
http://dx.doi.org/10.1002/onco.13883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417842/
https://www.ncbi.nlm.nih.gov/pubmed/34190370
http://dx.doi.org/10.1002/onco.13883

Ejemplares similares